Use of biomarkers for detecting ovarian cancer

Abstract

The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

1 - 77 . (canceled) 
     
     
         78 . A panel for characterizing ovarian cancer comprising biomarkers CA125 and HE4. 
     
     
         79 . The panel of claim  1 , further comprising biomarker prealbumin. 
     
     
         80 . The panel of claim  2 , further comprising a biomarker selected from the group consisting of CA125 II, CA15-3, CA19-9, CA72-4, CA 195, tumor associated trypsin inhibitor (TATI), CEA, placental alkaline phosphatase (PLAP), Sialyl TN, galactosyltransferase, macrophage colony stimulating factor (M-CSF, CSF-1), lysophosphatidic acid (LPA), 110 kD component of the extracellular domain of the epidermal growth factor receptor (p110EGFR), tissue kallikreins, kallikrein 6 and kallikrein 10 (NES-1), prostasin, creatine kinase B (CKB), LASA, HER-2/neu, urinary gonadotropin peptide, Dianon NB 70/K, Tissue peptide antigen (TPA), osteopontin and haptoglobin, and protein variants of the markers. 
     
     
         81 . A solid support comprising at least two capture molecules each of which specifically binds biomarkers CA125 and HE4. 
     
     
         82 . The solid support of  claim 81 , wherein the support further includes two capture molecules each of which specifically binds prealbumin. 
     
     
         83 . The solid support of  claim 81 , wherein the support is a biochip array, a microtiter plate, a stick, a bead, or a microbead. 
     
     
         84 . The solid support of  claim 81 , wherein the biochip array is a protein chip or nucleic acid array. 
     
     
         85 . The solid support of  claim 81 , wherein the capture molecule is an antibody or fragment thereof. 
     
     
         86 . A panel of capture molecules each of which specifically binds biomarkers CA125 and HE4. 
     
     
         87 . The panel of  claim 86 , wherein the panel further comprises capture molecules each of which specifically binds prealbumin. 
     
     
         88 . The panel of  claim 86 , wherein the capture molecules are antibodies or fragments thereof.